Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Sep;4(9):1711-30.
doi: 10.3390/v4091711. Epub 2012 Sep 24.

Human leukocyte antigen (HLA) class I down-regulation by human immunodeficiency virus type 1 negative factor (HIV-1 Nef): what might we learn from natural sequence variants?

Affiliations
Review

Human leukocyte antigen (HLA) class I down-regulation by human immunodeficiency virus type 1 negative factor (HIV-1 Nef): what might we learn from natural sequence variants?

Philip Mwimanzi et al. Viruses. 2012 Sep.

Erratum in

Abstract

HIV-1 causes a chronic infection in humans that is characterized by high plasma viremia, progressive loss of CD4+ T lymphocytes, and severe immunodeficiency resulting in opportunistic disease and AIDS. Viral persistence is mediated in part by the ability of the Nef protein to down-regulate HLA molecules on the infected cell surface, thereby allowing HIV-1 to evade recognition by antiviral CD8+ T lymphocytes. Extensive research has been conducted on Nef to determine protein domains that are required for its immune evasion activities and to identify critical cellular co-factors, and our mechanistic understanding of this process is becoming more complete. This review highlights our current knowledge of Nef-mediated HLA class I down-regulation and places this work in the context of naturally occurring sequence variation in this protein. We argue that efforts to fully understand the critical role of Nef for HIV-1 pathogenesis will require greater analysis of patient-derived sequences to elucidate subtle differences in immune evasion activity that may alter clinical outcome.

Keywords: HIV-1; HLA class I; Nef; cytotoxic T lymphocyte; host immune selection pressure; immune evasion; viral sequence diversity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Presentation of viral peptide antigens by Human Leukocyte Antigen (HLA) class I. Human immunodeficiency virus type 1 (HIV-1) proviral gene expression, including RNA transcription (a) and protein translation (b); generates functional viral proteins (c) as well as truncated or mis-folded proteins that are degraded by the cellular proteasome complex to form short antigenic peptides (d); These peptides are transported from the cytoplasm into the endoplasmic reticulum (ER) (e) where they can be loaded onto HLA-I molecules. Peptide/HLA complexes traffic from the ER through the Golgi and secretory vesicle (SV) network to the plasma cell membrane, where the peptide antigens are presented to circulating cytotoxic T lymphocytes (CTL) (f); The viral Nef protein shuttles HLA molecules located at the cell surface or within the trans-Golgi network into lysosomal compartments (g); where they are degraded. In the absence of Nef-mediated HLA down-regulation, antigen-specific CTL respond to stimulation by releasing cytotoxic molecules, including perforin and granzymes, resulting in elimination of the virus-infected cell (h).

References

    1. Dandekar S. Pathogenesis of HIV in the gastrointestinal tract. Curr. HIV/AIDS Rep. 2007;4:10–15. doi: 10.1007/s11904-007-0002-0. - DOI - PubMed
    1. Guadalupe M., Reay E., Sankaran S., Prindiville T., Flamm J., McNeil A., Dandekar S. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J. Virol. 2003;77:11708–11717. doi: 10.1128/JVI.77.21.11708-11717.2003. - DOI - PMC - PubMed
    1. Lim S.G., Condez A., Lee C.A., Johnson M.A., Elia C., Poulter L.W. Loss of mucosal CD4 lymphocytes is an early feature of HIV infection. Clin. Exp. Immunol. 1993;92:448–454. - PMC - PubMed
    1. Lyles R.H., Munoz A., Yamashita T.E., Bazmi H., Detels R., Rinaldo C.R., Margolick J.B., Phair J.P., Mellors J.W. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J. Infect. Dis. 2000;181:872–880. doi: 10.1086/315339. - DOI - PubMed
    1. Sierra-Aragon S., Walter H. Targets for inhibition of HIV replication: Entry, enzyme action, release and maturation. Intervirology. 2012;55:84–97. doi: 10.1159/000331995. - DOI - PubMed

Publication types

MeSH terms

Substances

Grants and funding